Patents by Inventor Edward Piers
Edward Piers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9040704Abstract: Herein are disclosed fluorescent dyes based around a framework for a ligand comprising a pyridyl group linked to a diaryl anilido unit. A variety of ligands based on this framework are disclosed. The ligands chelate to a BF2 center to produce the fluorescent dye. The disclosed dyes combine longer Stokes shifts (approximately 100 nm) with increased quantum yields. They are also photostable in aqueous and organic solutions for several hours. These dyes may be used in the labeling of biomolecules for bioimaging and assays. Also disclosed are methods for the synthesis of these dyes.Type: GrantFiled: August 10, 2012Date of Patent: May 26, 2015Assignee: UTI LIMITED PARTNERSHIPInventors: Warren Edward Piers, Juan Felipe Araneda
-
Publication number: 20140206870Abstract: Herein are disclosed fluorescent dyes based around a framework for a ligand comprising a pyridyl group linked to a diaryl anilido unit. A variety of ligands based on this framework are disclosed. The ligands chelate to a BF2 center to produce the fluorescent dye. The disclosed dyes combine longer Stokes shifts (approximately 100 nm) with increased quantum yields. They are also photostable in aqueous and organic solutions for several hours. These dyes may be used in the labeling of biomolecules for bioimaging and assays. Also disclosed are methods for the synthesis of these dyes.Type: ApplicationFiled: August 10, 2012Publication date: July 24, 2014Applicant: UTI LIMITED PARTNERSHIPInventors: Warren Edward Piers, Juan Felipe Araneda
-
Patent number: 7772397Abstract: This invention relates to derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by general formula I, wherein Y, n, R1, R2, R3, R6, R7, R70, R71, R72, R74, and R75 are as defined in the specification.Type: GrantFiled: July 21, 2008Date of Patent: August 10, 2010Assignee: University of British ColumbiaInventors: Raymond Andersen, John Coleman, Dilip De Silva, Fangming Kong, Edward Piers, Debra Wallace, Michel Roberge, Theresa Allen
-
Publication number: 20090264487Abstract: This invention provides analogs of hemiasterlin, methods of synthesis of the analogs and use of the analogs as a cytotoxic anti-mitotic agents.Type: ApplicationFiled: June 25, 2009Publication date: October 22, 2009Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Raymond ANDERSEN, Edward Piers, James Nieman, John Coleman, Michel Roberge
-
Patent number: 7579323Abstract: This invention provides analogs of hemiasterlin, methods of synthesis of the analogs and use of the analogs as cytotoxic and anti-mitotic agents.Type: GrantFiled: December 13, 1998Date of Patent: August 25, 2009Assignee: The University of British ColumbiaInventors: Raymond Andersen, Edward Piers, James Nieman, John Coleman, Michel Roberge
-
Publication number: 20090088573Abstract: This invention relates to derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by general formula I, wherein Y, n, R1, R2, R3, R6, R7, R70, R71, R72, R74, and R75 are as defined in the specification.Type: ApplicationFiled: July 21, 2008Publication date: April 2, 2009Applicant: The University of British ColumbiaInventors: Raymond ANDERSEN, John Coleman, Dilip De Silva, Fangming Kong, Edward Piers, Debra Wallace, Michel Roberge, Theresa Allen
-
Patent number: 7410951Abstract: Derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by formula I wherein Y, n, R1, R2, R3, R7, R70, R71, R72, R74, and R75 are as defined in the specification.Type: GrantFiled: January 14, 2005Date of Patent: August 12, 2008Assignee: The University of British ColumbiaInventors: Raymond Andersen, John Coleman, Dilip De Silva, Fangming Kong, Edward Piers, Debra Wallace, Michel Roberge, Theresa Allen
-
Patent number: 7365140Abstract: Organometallic complexes suitable as olefin metathesis catalysts are provided. The complexes are Group 8 transition metal carbenes bearing a cationic substituent and having the general structure (I) wherein M is a Group 8 transition metal, L1 and L2 are neutral electron donor ligands, X1 and X2 are anionic ligands, m is zero or 1, n is zero or 1, and R1, W, Y, and Z are as defined herein. Methods for synthesizing the complexes are also provided, as are methods for using the complexes as olefin metathesis catalysts.Type: GrantFiled: June 9, 2005Date of Patent: April 29, 2008Assignee: UTI Limited PartnershipInventors: Warren Edward Piers, Patricio Eduardo Romero Guajardo
-
Publication number: 20060211857Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: ApplicationFiled: November 22, 2005Publication date: September 21, 2006Applicants: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David Burgoyne, Yaping Shen, John Langlands, Christine Rogers, Joseph Chau, Edward Piers, Hassan Salari
-
Patent number: 7078546Abstract: The compound 1,2-bis(9-bora-1,2,3,4,5,6,7,8-octafluorofluorenyl)-3,4,5,6-tetrafluorobenzene, analogs of the compound, and methods for making the compound and its analogs.Type: GrantFiled: April 2, 2004Date of Patent: July 18, 2006Assignee: University Technologies International Inc.Inventors: Warren Edward Piers, Preston A. Chase, Lee Douglas Henderson
-
Patent number: 7067682Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: November 6, 2003Date of Patent: June 27, 2006Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H L Chau, Edward Piers, Hassan Salari
-
Patent number: 6949533Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: November 6, 2003Date of Patent: September 27, 2005Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
-
Publication number: 20050171137Abstract: This invention relates to derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by general formula I, wherein Y, n, R1, R2, R3, R6, R7, R70, R71, R72, R74, and R75 are as defined in the specification.Type: ApplicationFiled: January 14, 2005Publication date: August 4, 2005Inventors: Raymond Andersen, John Coleman, Dilip De Silva, Fangming Kong, Edward Piers, Debra Wallace, Michael Roberge, Teresa Allen
-
Patent number: 6870028Abstract: This invention relates to derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by general formula I, wherein Y, n, R1, R2, R3, R6, R7, R70, R71, R72, R74, and R75 are as defined in the specification.Type: GrantFiled: June 14, 2000Date of Patent: March 22, 2005Assignees: University of British Columbia, University of AlbertaInventors: Raymond Andersen, John Coleman, Dilip De Silva, Fangming Kong, Edward Piers, Debra Wallace, Michael Roberge, Theresa Allen
-
Publication number: 20040162425Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: ApplicationFiled: November 6, 2003Publication date: August 19, 2004Applicants: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
-
Publication number: 20040157814Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: ApplicationFiled: November 6, 2003Publication date: August 12, 2004Applicants: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.L. Chau, Edward Piers, Hassan Salari
-
Patent number: 6706701Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: December 23, 1999Date of Patent: March 16, 2004Assignees: Inflazyme Pharmaceuticals Ltd., University of British Columbia, University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
-
Patent number: 6291447Abstract: Novel granulatimide compounds and pharmaceutical formulations thereof are provided.Type: GrantFiled: February 26, 1999Date of Patent: September 18, 2001Assignees: The University of British Columbia, Kinetek Pharmaceuticals, Inc.Inventors: Raymond Andersen, Michel Roberge, Jasbinder Sanghera, Daniel Leung, Edward Piers, Roberto GS Berlinck, Robert Britton
-
Patent number: 6153590Abstract: Compounds of general formula I ##STR1## wherein: R.sub.1 and R.sub.70 independently represent a hydrogen atom or an optionally substituted alkyl or acyl group; R.sub.2 represents a hydrogen atom or an optionally substituted alkyl or acyl group or is absent when R.sub.6 represents a group --CH.dbd. as hereinafter described; R.sub.73 represents a hydrogen atom or an optional substituent or is absent when R.sub.6 represents a methylene group or a group --CH.dbd. as hereinafter described; Y represents an optional substituent; n represents 0, 1, 2, 3, or 4; R.sub.3 represents a hydrogen atom, or an optionally substituted alkyl group; R.sub.74 represents a hydrogen atom, a hydroxy group or an optionally substituted alkyl or acyl group; R.sub.7 represents a hydrogen atom or an alkyl group; R.sub.75 represents an optionally substituted alkyl group; and i) R.sub.6 and R.sub.71 independently represent a hydrogen atom or an optionally substituted alkyl or acyl group; and R.sub.72 represents a hydrogen atom; or ii) R.Type: GrantFiled: February 2, 1998Date of Patent: November 28, 2000Assignees: University of Alberta, University of British ColumbiaInventors: Raymond Andersen, John Coleman, Dilip De Silva, Fangming Kong, Edward Piers, Debra Wallace, Michel Roberge, Teresa Allen
-
Patent number: 6046185Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6.alpha. and 7.beta. oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6.alpha. and 7.beta. oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and .delta.-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: July 10, 1997Date of Patent: April 4, 2000Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari